# Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

Source: https://onco.cc/trials/nct07181161/  
OnCo record `nct07181161` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests a PARP inhibitor; the registry reports that it is recruiting.

## Summary

The registry lists NCT07181161 as recruiting, last updated 2026-09-25. Enrolment is 283 planned participants, an estimate. Interventions: AZD0516, AZD9574. Primary measures include Module 1 and 2: Parts A and B: Number of participants with Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Event of Special Interests (AESIs); Module 1 and 2: Part A: Number of participants with Dose Limiting Toxicities (DLTs). No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Also known as: SEACLIFF
- Tags: ctgov-ingest
- Registry id: NCT07181161
- Phase: 1/2
- Setting: A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0516 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Metastatic Prostate Cancer
- Sponsor: AstraZeneca

## Sources

- ClinicalTrials.gov NCT07181161: https://clinicaltrials.gov/study/NCT07181161

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [Palacaparib](https://onco.cc/drugs/palacaparib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct07181161.json